# BioInvent International

Source: https://onco.cc/companies/bioinvent-international/  
OnCo record `bioinvent-international` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BioInvent International is a Sweden-based biotechnology company running 4 late-stage cancer trials of BI-1607, Ipilimumab (YervoyTM and BI-1910 in melanoma, uveal melanoma and non-small-cell lung cancer.

## Summary

BioInvent International, based in Lund, Sweden, is a biotechnology company. BioInvent International is a clinical-stage company that discovers and develops antibodies for cancer immunotherapy, using its proprietary F.I.R.S.T. platform and n-CoDeR antibody library. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing BI-1607, Ipilimumab (YervoyTM, BI-1910, BI1206 and BI-1808 in melanoma, uveal melanoma, non-small-cell lung cancer, hepatocellular carcinoma and ovarian cancer. The largest, NCT04219254 (A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours), plans to enrol 197 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: BioInvent International AB
- Tags: ctgov-sponsor
- HQ: Lund
- Type: biotech
- Website: https://www.bioinvent.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Bioinvent
- Official website: https://www.bioinvent.com
- ClinicalTrials.gov: trials led by BioInvent International: https://clinicaltrials.gov/search?lead=BioInvent%20International%20AB

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- trials: [A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct04219254/), [BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)](https://onco.cc/trials/nct04752826/), [BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct06205706/), [Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma](https://onco.cc/trials/nct06784648/)

---
JSON: https://onco.cc/api/v1/entities/bioinvent-international.json